Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review)
Open Access
- 18 August 2026
- journal article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (4) , 1-17
Abstract
Inflammatory bowel disease (IBD) is a group of chronic, relapsing and systemic inflammatory disorders primarily affecting the gastrointestinal tract, including Crohn's disease, ulcerative colitis and rarer distinct subtypes such as indeterminate colitis. IBD has shown a marked shift in global epidemiology, with increasing incidence in newly industrialized regions across Africa, Asia and Latin America. The pathogenesis of IBD reflects a complex interplay between genetic susceptibility, mucosal immune dysregulation, intestinal barrier dysfunction, microbial dysbiosis and environmental exposures. Clinically, conventional therapy, including 5‑aminosalicylic acid, corticosteroids and conventional immunosuppressants, is limited by incomplete efficacy and safety concerns. Alternative therapeutic strategies included biological agents (anti‑tumor necrosis factor α, anti‑integrin, anti‑IL‑12/23 and anti‑tumor necrosis factor‑like ligand 1A), small‑molecule inhibitors (JAK inhibitors, tyrosine kinase 2 inhibitors, sphingosine‑1‑phosphate receptor modulators and NLRP3 inhibitors), microbiome‑based interventions (fecal microbiota transplantation, probiotics and engineered microbes) and regenerative approaches (mesenchymal stem cells and intestinal organoids). The present review aimed to summarize mechanistic insights and clinical evidence for established and emerging therapies and discusses current challenges and future directions for individualized, disease‑modifying treatment of IBD.Keywords
This publication has 190 references indexed in Scilit:
- Development of a highly efficient base editing system for Lactobacilli to improve probiotics and dissect essential functionsApplied Microbiology and Biotechnology, 2025
- Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBDDigestive Diseases and Sciences, 2024
- Multi‐Omics Biomarkers for Predicting Efficacy of Biologic and Small‐Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic ReviewUnited European Gastroenterology Journal, 2024
- Fecal microbiota transplantation for induction of remission in Crohn’s disease: a systematic review and meta-analysisInternational Journal of Colorectal Disease, 2023
- The clinical utility of polygenic risk scores in genomic medicine practices: a systematic reviewHuman Genetics, 2022
- Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory DiseasesJAMA, 2021
- Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative ColitisJAMA, 2019
- Comparison of polyglycolic acid, polycaprolactone, and collagen as scaffolds for the production of tissue engineered intestineJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2018
- Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel diseaseJournal of Gastroenterology, 2018
- Bacterial acetylation of 5-aminosalicylic acid in faecal suspensions cultured under aerobic and anaerobic conditionsEuropean Journal of Clinical Pharmacology, 1992